Welcome to our dedicated page for CeriBell news (Ticker: CBLL), a resource for investors and traders seeking the latest updates and insights on CeriBell stock.
CeriBell, Inc. (Nasdaq: CBLL) is a medical technology company that develops the Ceribell System, a point-of-care electroencephalography (EEG) platform for patients with serious neurological conditions in acute care settings. This news page aggregates company announcements, clinical and regulatory milestones, and financial updates that relate to CeriBell’s AI-powered brain monitoring technology.
Readers can find coverage of key regulatory events, such as FDA 510(k) clearances for the company’s next-generation Clarity® algorithm to detect electrographic seizures in pre-term neonates through adults and for its proprietary delirium screening and monitoring solution. The news feed also includes information on the FDA Breakthrough Device Designation granted to CeriBell’s Large Vessel Occlusion (LVO) stroke detection monitor, which uses existing Ceribell hardware and an AI-based algorithm to interpret EEG signals for early LVO stroke detection in hospitalized patients.
In addition to regulatory developments, CeriBell’s news includes quarterly financial results that distinguish between product and subscription revenue, updates on adoption of the Ceribell System in intensive care units and emergency rooms across the U.S., and disclosures about corporate agreements and intellectual property matters. Examples include supply agreements for EEG headbands, licensing arrangements with Stanford University, and patent-related legal actions.
Investors and healthcare professionals can also follow announcements about CeriBell’s participation in healthcare and medtech conferences, as well as board and governance updates. This page offers a centralized view of how the company’s point-of-care EEG platform, AI algorithms, and commercial activities are evolving over time, providing context for CBLL stock watchers and those tracking advancements in neurocritical care devices.
Ceribell (Nasdaq: CBLL), a commercial-stage medical technology company focusing on neurological condition diagnosis and management, has scheduled its Q3 2024 financial results release for November 12, 2024, after market close. The company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. Investors can join via phone using access code 7168007 or watch the webcast through Ceribell's investor relations website.
Ceribell (Nasdaq: CBLL) presented five abstracts at the 2024 Neurocritical Care Society Annual Meeting, showcasing new clinical evidence for its point-of-care EEG system and AI-powered Clarity™ algorithm. Key findings include:
1. Shorter median hospital stays and 33% lower likelihood of significant functional disability at discharge for patients monitored with Ceribell.
2. Link between Clarity seizure burden and poor functional outcomes.
3. Reliable signal quality for up to 24 hours of continuous monitoring.
4. Variability in clinicians' EEG interpretation, highlighting the need for AI standardization.
5. Improved detection of status epilepticus with the latest Clarity version.
The Ceribell System, FDA 510(k) cleared for indicating suspected seizure activity, has been adopted by over 500 hospitals and used to diagnose and monitor over 100,000 patients.
CeriBell, Inc. (Nasdaq: CBLL), a medical technology company focused on neurological conditions, has successfully closed its upsized initial public offering (IPO). The company sold 12,196,969 shares of common stock at $17.00 per share, including 1,590,909 additional shares from the full exercise of the underwriters' option. The IPO raised approximately $207.3 million in gross proceeds before deducting underwriting discounts, commissions, and other expenses.
CeriBell's common stock began trading on the Nasdaq Global Select Market on October 11, 2024, under the ticker symbol CBLL. BofA Securities and J.P. Morgan served as joint book-running managers and representatives of the underwriters, with William Blair, TD Cowen, and Canaccord Genuity acting as co-managers for the offering.
CeriBell, Inc. (Nasdaq: CBLL), a commercial-stage medical technology company, has announced the pricing of its upsized initial public offering. The company is offering 10,606,060 shares of common stock at a public offering price of $17.00 per share. CeriBell has also granted underwriters a 30-day option to purchase up to an additional 1,590,909 shares at the initial offering price.
Trading of the shares is expected to begin on the Nasdaq Global Select Market on October 11, 2024, under the ticker symbol 'CBLL'. The gross proceeds from the offering are anticipated to be approximately $180.3 million, excluding any exercise of the underwriters' option. The offering is expected to close on October 15, 2024, subject to customary closing conditions.
BofA Securities and J.P. Morgan are acting as joint book-running managers and representatives of the underwriters, with William Blair, TD Cowen, and Canaccord Genuity serving as co-managers for the offering.